Objective： To evaluate the clinical effect of Buyi Qiangxin tablets for chronic heart failure and its safety.Methods： Searched the database including CNKI，Wanfang，VIP， PubMed， EMbase and The Cochrane Library for the relevant research literature of randomized controlled trials on Buyi Qiangxin tablets combined with basic western medicine for chronic heart failure and on patients with cardiac function II and III from establishment to January 2016 Meta-analysis in the language of English and Chinese by computer； according to inclusive criteria and exclusive criteria， two researchers separately screened the literature，extracted data and evaluated the quality， and the meta-analysis was conducted via RevMan 5.3 software.Results：Finally included 7 categories of randomized controlled research literature， 483 cases of patients in total.The clinical effect：the one with Buyi Qiangxin tablets was better than that in the control group[OR=4.54，95%CII(2.33，9.26)，P ＜ 0.01]；left ventricular ejection fraction(LVEF)：[MD=3.88，95%CI(3.18，4.59)，P ＜ 0.01]；life quality： [MD=-11.23， 95%CI(-14.45， -8.01)， P ＜ 0.01]； the clinical effect of cardiac function： [OR=4.44， 95%CI(1.63，11.93)，P ＜ 0.01]，NT-proBNP：[SMD=-1.58，95%CI(-1.88，-1.282)，P ＜ 0.01].Conclusion：Buyi Qiangxin tablets has satisfactory clinical effect，and can improve the clinical effect of heart failure，ventricular ejection fraction and the clinical effect of cardiac function in patients with chronic heart failure.But limited by factors including the quality of literature in the research，lack of patients and so on，the conclusion mentioned above still needs more researches of high quality to be justified.